[go: up one dir, main page]

DK2929891T3 - Fremgangsmåde til modulering af appetitten - Google Patents

Fremgangsmåde til modulering af appetitten Download PDF

Info

Publication number
DK2929891T3
DK2929891T3 DK15163748.5T DK15163748T DK2929891T3 DK 2929891 T3 DK2929891 T3 DK 2929891T3 DK 15163748 T DK15163748 T DK 15163748T DK 2929891 T3 DK2929891 T3 DK 2929891T3
Authority
DK
Denmark
Prior art keywords
modulating
appearance
procedure
Prior art date
Application number
DK15163748.5T
Other languages
English (en)
Inventor
Samuel Norbert Breit
Asne Rhoda Bauskin
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2929891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Application granted granted Critical
Publication of DK2929891T3 publication Critical patent/DK2929891T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15163748.5T 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten DK2929891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
DK2929891T3 true DK2929891T3 (da) 2020-05-11

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel

Country Status (11)

Country Link
US (7) US8192735B2 (da)
EP (4) EP2441466B1 (da)
JP (4) JP5448338B2 (da)
CA (2) CA2905125C (da)
CY (1) CY1115731T1 (da)
DK (2) DK2929891T3 (da)
ES (3) ES2555956T3 (da)
PL (2) PL2929891T3 (da)
PT (2) PT2441466E (da)
SI (1) SI2441466T1 (da)
WO (1) WO2005099746A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
CA2660691C (en) * 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
WO2009021293A1 (en) * 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
MX343729B (es) * 2011-04-08 2016-11-18 Amgen Inc Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3590537A1 (en) 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
EP3157952B1 (en) * 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
EP3157953B1 (en) * 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157942B1 (en) * 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
EP3197493B1 (en) 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
ES2799503T3 (es) 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
US20170334971A1 (en) * 2014-12-22 2017-11-23 Novo Nordisk A/S Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
AU2016333538B2 (en) 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
BR112018006218A2 (pt) 2015-10-02 2018-10-09 Univ Wuerzburg J Maximilians iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
US11604194B2 (en) 2016-02-29 2023-03-14 Public University Corporation Yokohama City University Method for detecting castration-resistant prostate cancer and detection reagent
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
JP2020503842A (ja) * 2016-10-12 2020-02-06 ヤンセン バイオテツク，インコーポレーテツド Ｇｄｆ１５様生物活性の調節因子をスクリーニングするための方法
CA3045700A1 (en) 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
MA50233A (fr) 2017-09-10 2020-07-22 Novo Nordisk As Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
KR102715542B1 (ko) 2018-08-20 2024-10-08 화이자 인코포레이티드 항-gdf15 항체, 조성물 및 사용 방법
US10706329B2 (en) * 2018-11-13 2020-07-07 CurieAI, Inc. Methods for explainability of deep-learning models
AU2020394255A1 (en) 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
BR112023020152A2 (pt) 2021-03-31 2023-11-14 Cambridge Entpr Ltd Inibidores terapêuticos de sinalização gdf15
CA3219685A1 (en) 2021-05-21 2022-11-24 Seyoung LIM Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2022245179A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
US20250019427A1 (en) 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
AU1103900A (en) 1998-10-07 2000-04-26 Stryker Corporation Modified tgf-beta superfamily proteins
JP4920851B2 (ja) * 2000-04-20 2012-04-18 セイント ヴィンセンツ ホスピタル シドニー リミテッド マクロファージ抑制サイトカイン−１（ｍｉｃ−１）が関連する検査方法
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
SI1844337T1 (sl) * 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE

Also Published As

Publication number Publication date
US20210340243A1 (en) 2021-11-04
PT2441466E (pt) 2014-09-09
EP2929891B1 (en) 2020-03-11
WO2005099746A1 (en) 2005-10-27
HK1215932A1 (en) 2016-09-30
PT2929891T (pt) 2020-04-08
CY1115731T1 (el) 2017-01-25
PL2441466T3 (pl) 2015-01-30
JP2013209376A (ja) 2013-10-10
EP1734986A4 (en) 2009-07-22
JP5806275B2 (ja) 2015-11-10
US20160289320A1 (en) 2016-10-06
PL2929891T3 (pl) 2020-08-24
US20110123454A1 (en) 2011-05-26
US20250109192A1 (en) 2025-04-03
CA2905125C (en) 2017-02-07
US8192735B2 (en) 2012-06-05
CA2905125A1 (en) 2005-10-27
JP5767667B2 (ja) 2015-08-19
CA2561877A1 (en) 2005-10-27
CA2561877C (en) 2017-03-14
SI2441466T1 (sl) 2015-01-30
EP1734986A1 (en) 2006-12-27
US8946146B2 (en) 2015-02-03
EP2441466B1 (en) 2014-07-23
US20150183861A1 (en) 2015-07-02
EP1734986B1 (en) 2015-11-11
DK2441466T3 (da) 2014-10-27
EP2441466A1 (en) 2012-04-18
ES2555956T3 (es) 2016-01-11
JP2007532586A (ja) 2007-11-15
EP2929891A1 (en) 2015-10-14
JP2011190262A (ja) 2011-09-29
EP2774620A1 (en) 2014-09-10
JP2014051511A (ja) 2014-03-20
ES2518865T3 (es) 2014-11-05
ES2788868T3 (es) 2020-10-23
US20180346560A1 (en) 2018-12-06
US20090004181A1 (en) 2009-01-01
HK1168274A1 (en) 2012-12-28
JP5448338B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
DK2929891T3 (da) Fremgangsmåde til modulering af appetitten
EP1958024A4 (en) ADVANCED ZSCREEN MODULATOR PROCEDURES
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1753936T3 (da) Tætningssystem
DK1809978T3 (da) Modul-skydebane
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DE602005012636D1 (de) Erung
DE602005011236D1 (de) Modulationsbereichstrigger
DK1593898T3 (da) Tætningselement
ATE442044T1 (de) Herbizid-safener-kombination
NL1029457A1 (nl) Androgeenmodulatoren.
DE602005012462D1 (de) Luftdämpfer
DK2447252T3 (da) Theramuteinmodulatorer
EP1718391A4 (en) SPRAY DEVICE
DK1834528T3 (da) Fremgangsmåde til fremstilling af gelé-agtige drikke
DK1789529T3 (da) Fremgangsmåde til forbedring af konserveringen af lactococcus
SE0400476L (sv) Komponent
DE602005010220D1 (de) Dichtung
SE0400530L (sv) Förfarande
ATE521769T1 (de) Beschlag
AT500162B8 (de) Gleitringdichtung
DE602005000799D1 (de) Flanschstruktur
DE602005000841D1 (de) Dichtung
DE602005002416T8 (de) Zündanordnung
AT500198B1 (de) Ladewagen